Protara Therapeutics (TARA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TARA Protara Therapeutics

Watchlist

3.540
+0.720+25.53%

Close Dec 4 16:00 ET

3.640
+0.100+2.82%

Post 20:02 ET

73.03MMarket Cap-1340P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Protara Therapeutics To Host Conference Call And Webcast To Review New Interim Data From Phase 2 ADVANCED-2 Trial Of TARA-002 In Patients With NMIBC On December 5, 2024 At 8:30 A.m. ET
BenzingaDec 3 08:26 ET
Express News | HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
BenzingaNov 14 06:55 ET
Oppenheimer Maintains Protara Therapeutics(TARA.US) With Buy Rating, Cuts Target Price to $25
Moomoo NewsNov 13 08:31 ET · Ratings
Oppenheimer Sticks to Their Buy Rating for Protara Therapeutics (TARA)
TipRanksNov 13 08:08 ET · Ratings
Protara Therapeutics | 8-K: Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
SECNov 12 11:57 ET
Protara Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 12 09:42 ET · Announcements

Comments

Jaguar8

Dec 3 07:00

NEWS

$Protara Therapeutics (TARA.US)$
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024
Tuesday, 3rd December at 8:00 am
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live ...

Jaguar8

Nov 15 18:04

NEWS

$Protara Therapeutics (TARA.US)$
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
Protara Therapeutics (Nasdaq: TARA) announced upcoming presentation of interim data from its Phase 2 ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC) at the Society of Urologic Oncology Annual Meeting. The presentation will include safety data and new efficacy...

Stock_Drift

Nov 15 17:13

$Protara Therapeutics (TARA.US)$

Jaguar8

Sep 9 07:04

NEWS

$Protara Therapeutics (TARA.US)$
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
• 78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunction, including steatosis, cholestasis, and hepatobiliary injury
• IV Choline Chloride could fill a significant unmet medical need for th...